Peer Review History

Original SubmissionApril 11, 2021
Decision Letter - Seyed Ehtesham Hasnain, Editor

PONE-D-21-10427

Assessing a chip based rapid  RTPCR test for SARS C0V-2 detection (TrueNat assay): a diagnostic accuracy study.

PLOS ONE

Dear Dr. Garg,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Jul 11 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Seyed Ehtesham Hasnain, Ph.D

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. We suggest you thoroughly copyedit your manuscript for language usage, spelling, and grammar. If you do not know anyone who can help you do this, you may wish to consider employing a professional scientific editing service.  

Whilst you may use any professional scientific editing service of your choice, PLOS has partnered with both American Journal Experts (AJE) and Editage to provide discounted services to PLOS authors. Both organizations have experience helping authors meet PLOS guidelines and can provide language editing, translation, manuscript formatting, and figure formatting to ensure your manuscript meets our submission guidelines. To take advantage of our partnership with AJE, visit the AJE website (http://learn.aje.com/plos/) for a 15% discount off AJE services. To take advantage of our partnership with Editage, visit the Editage website (www.editage.com) and enter referral code PLOSEDIT for a 15% discount off Editage services.  If the PLOS editorial team finds any language issues in text that either AJE or Editage has edited, the service provider will re-edit the text for free.

Upon resubmission, please provide the following:

  • The name of the colleague or the details of the professional service that edited your manuscript
  • A copy of your manuscript showing your changes by either highlighting them or using track changes (uploaded as a *supporting information* file)
  • A clean copy of the edited manuscript (uploaded as the new *manuscript* file)

3. We note that Figure 1 in your submission contains copyrighted images. All PLOS content is published under the Creative Commons Attribution License (CC BY 4.0), which means that the manuscript, images, and Supporting Information files will be freely available online, and any third party is permitted to access, download, copy, distribute, and use these materials in any way, even commercially, with proper attribution. For more information, see our copyright guidelines: http://journals.plos.org/plosone/s/licenses-and-copyright.

We require you to either (a) present written permission from the copyright holder to publish this figure specifically under the CC BY 4.0 license, or (b) remove the figure from your submission:

a. You may seek permission from the original copyright holder of Figure 1 to publish the content specifically under the CC BY 4.0 license.

We recommend that you contact the original copyright holder with the Content Permission Form (http://journals.plos.org/plosone/s/file?id=7c09/content-permission-form.pdf) and the following text:

“I request permission for the open-access journal PLOS ONE to publish XXX under the Creative Commons Attribution License (CCAL) CC BY 4.0 (http://creativecommons.org/licenses/by/4.0/). Please be aware that this license allows unrestricted use and distribution, even commercially, by third parties. Please reply and provide explicit written permission to publish XXX under a CC BY license and complete the attached form.”

Please upload the completed Content Permission Form or other proof of granted permissions as an "Other" file with your submission. 

In the figure caption of the copyrighted figure, please include the following text: “Reprinted from [ref] under a CC BY license, with permission from [name of publisher], original copyright [original copyright year].”

b.  If you are unable to obtain permission from the original copyright holder to publish this figure under the CC BY 4.0 license or if the copyright holder’s requirements are incompatible with the CC BY 4.0 license, please either i) remove the figure or ii) supply a replacement figure that complies with the CC BY 4.0 license. Please check copyright information on all replacement figures and update the figure caption with source information. If applicable, please specify in the figure caption text when a figure is similar but not identical to the original image and is therefore for illustrative purposes only.

Additional Editor Comments:

Major Revision

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: No

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Comments:

Present study of Ghoshal U et al. is based on diagnostic approach to encounter present pandemic globally. It is a comparative study between to molecular diagnostics and more informative while testing COVID 19 virus. However, manuscript is written in a very casual approach.

Abstract:

• Abbreviation of PCR should write at proper sections (Line no. 30, 31, 33, 35).

• Author can modify the Conclusion section.

Introduction:

• Advised to write the current global as we as India epidemiological data (Line no. 46, 47).

• It is advised to authors to modify the sentence, as it seems duplicated from abstract section (COVID-19 testing is required before admission of a patient…..).

• Advised to write the updated name of RNTCP.

Material and Methods:

• Author should write the abbreviation RTPCR trough out the manuscript (WHO, OPD etc).

• It is advised to write abbreviation in a single way (line no. 46, 47, 129, 130).

• Write NPV and PPV in statistical analysis section also.

Results and Discussion:

• It is advised to author that please recheck the percentage as well as sample number before writing the result.

• Don’t use full stop sign (.) within a single sentence (Line no. 166-169).

• It is advised to avoid the duplication of sentences (Line no. 181- 190).

• Modify the sentence (Further only 30 positive samples were tested and these reasons might have…..).

• Reference should write as per the journal guideline.

• Reference required for actual Operational cost for TrueNat test and RTPCR.

Reviewer #2: This study is in time and address issue of quick and handy detection of the samples which can be helpful in accessing the infection rate and frequency. However i have one major concern which need clarification from author .

Whether author compared the fidelity of this assay with the RAT ( rapid antigen test ) , how correlative and reliable is this assay. Whether the author used simple PCR or modified nested one. Can we identify mutated strain also in the patients.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Revision 1

POINT WISE ANSWERS TO REVIEWER COMMENTS

Reviewer 1:

1. Abbreviation of PCR should BE written at proper sections (Line no. 30, 31, 33, 35).

Answer: We have corrected the manuscript as suggested

2. Author can modify the Conclusion section of abstract.

Answer: We have modified the conclusion in abstract.

3. Advised to write the current global as well as India epidemiological data (Line no. 46, 47).

Answer: We have updated the global data and added Indian data as per your suggestion.

4. It is advised to authors to modify the sentence, as it seems duplicated from abstract section (COVID-19 testing is required before admission of a patient…..).

Answer: We have modified the sentence in revised manuscript.

5. Advised to write the updated name of RNTCP.

Ans: Name updated as National Tuberculosis Elimination Programme.

6. Author should write the abbreviation RTPCR trough out the manuscript (WHO, OPD etc).

Answer: We have incorporated this change in revised manuscript.

7. It is advised to write abbreviation in a single way (line no. 46, 47, 129, 130).

Answer: We have taken care to write abbreviation in single way in revised manuscript.

8. Write NPV and PPV in statistical analysis section also.

Answer: We have incorporated this change in revised manuscript.

9. It is advised to author that please recheck the percentage as well as sample number before writing the result.

Answer: Thank you for pointing out the typing mistake. We have corrected the data in revised manuscript.

10. Don’t use full stop sign (.) within a single sentence (Line no. 166-169).

Answer: We have incorporated this change in revised manuscript.

11. It is advised to avoid the duplication of sentences (Line no. 181- 190).

Answer: While revising the manuscript we have removed the duplicate sentences.

12. Modify the sentence (Further only 30 positive samples were tested and these reasons might have…..).

Answer: We have revised the sentence in revised manuscript.

13. Reference should be written as per the journal guideline.

Answer: Reference formatted as per Journal guidelines.

14. Reference required for actual Operational cost for TrueNat test and RTPCR.

Answer: Reference added in revised manuscript.

Reviewer 2:

This study is in time and address issue of quick and handy detection of the samples which can be helpful in accessing the infection rate and frequency. However, one major concern which need clarification from author.

1. Whether author compared the fidelity of this assay with the RAT (rapid antigen test), how correlative and reliable is this assay.

Answer: In this study in small subset of patients (n=30) all three test i.e. antigen detection by STANDARD Q COVID-19 Ag Test (SD Biosensor, South Korea), Truenat test and RTPCR was done. Taking RTPCR results as gold standard; Antigen detection and Truenat test showed sensitivity of 55% and 70 % respectively. The specificity in each test was 100%. Antigen detection missed 2 RTPCR positive cases (Ct value 29 and 31) but were detected by Truenat test. However, as the sample size is small this data is not included in manuscript.

2. Whether the author used simple PCR or modified nested one.

Answer: We used simple RTPCR protocol suggested by Indian council of medical research, India. All samples were tested for E gene and RdRP gene and cut off threshold <40 was considered as positive.

3. Can we identify mutated strain also in the patients.

Answer: Mutated strains of SARS Cov-2 cannot be identified by Truenat testing or routine RTPCR test.

Attachments
Attachment
Submitted filename: PLOS POINT WISE ANSWERS TO REVIEWER COMMENTS.docx
Decision Letter - Seyed Ehtesham Hasnain, Editor

Assessing a chip based rapid  RTPCR test for SARS C0V-2 detection (TrueNat assay): a diagnostic accuracy study.

PONE-D-21-10427R1

Dear Dr. Garg,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Seyed Ehtesham Hasnain

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

I have gone through the revised manuscript and also the author's response to the comments of the reviewers. The manuscript was sent for revision and Authors have modified the manuscript keeping in mind the comments of the Reviewers. Conclusion section of the Abstract has been modified and Authors have updated the global data and added Indian data in the manuscript. Reference part has been updated. All grammatical and spelling errors have been taken care off.

In my view, the authors have satisfactorily addressed all the comments made by the reviewers and added all required information, and have revised the manuscript accordingly. I recommend this manuscript for publication.

Reviewers' comments:

Formally Accepted
Acceptance Letter - Seyed Ehtesham Hasnain, Editor

PONE-D-21-10427R1

Assessing a chip based rapid  RTPCR test for SARS C0V-2 detection (TrueNat assay): a diagnostic accuracy study.

Dear Dr. Garg:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Prof. Seyed Ehtesham Hasnain

Academic Editor

PLOS ONE

Open letter on the publication of peer review reports

PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.

We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.

Learn more at ASAPbio .